Biodefense is a military or emergency response term that is frequently discussed in the context of bio-war or bioterrorism. Biodefense also refers to actions taken to restore biosecurity to a group of organisms that are or may be vulnerable to biological threats or infectious diseases. A biological attack, also known as bioterrorism, is the deliberate release of viruses, bacteria, or other germs capable of sickening or killing people, livestock, or crops. The bacteria that causes anthrax, Bacillus anthracis, is considered as one of the most likely agents to be used in a biological attack.
Market Dynamics
Market players and some global foundations are focused on developing vaccines against Nipah Virus, this could contribute to the growth of the global biodefense market over the forecast period. For instance on March 13, 2020, the Coalition for Epidemic Preparedness Innovations (CEPI), a global foundation that takes donations from philanthropic organizations, funded the first Nipah virus vaccine candidate to enter Phase 1 clinical trials. The Phase 1 trial is a randomized, placebo-controlled dose-finding study to assess the safety, tolerability, and immunogenicity of the HeV-sG-V Nipah vaccine candidate. The study is being conducted at Cincinnati Children's Hospital Medical Center in Cincinnati, U.S., and is sponsored by Auro Vaccines LLC, a wholly owned indirect subsidiary of Aurobindo Pharma Ltd., and led by Program for Appropriate Technology in Health (PATH), a global non-profit organization.
Market players are focusing on product launches, which is expected to strengthen their position in the global biodefense market. For instance, on July 01, 2020, Johnson & Johnson, world’s largest healthcare company announced that the European Commission (EC) approved its subsidiary Janssen Pharmaceutical Companies' Ebola vaccine regimen for the prevention of Ebola Virus Disease.
Market players are involved in expanding their global presence by adopting strategies such as acquisitions and partnerships, this is expected to drive the growth of the global biodefense market. For instance, on February 26, 2020, Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, partnered with Southern Research, a non-profit scientific research organization, to develop a potential COVID-19 vaccine based on Tonix's proprietary horsepox vaccine platform (TNX-1800).
Key features of the study:
- This report provides an in-depth analysis of global biodefense market, provides market size (US$ Billion), and compound annual growth rate (CAGR %) for the forecast period (2021-2028), considering 2020 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global biodefense market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
- Key companies covered as a part of this study include Emergent Biosolutions Inc., SIGA Technologies Inc., Bavarian Nordic A/S, Elusys Therapeutics Inc., Ichor Medical Systems Inc., Amgen Inc., Cleveland BioLabs Inc., Dynavax Technologies Corporation, Alnylam Pharmaceuticals Inc., and XOMA Corporation.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
- The global biodefense market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global biodefense market.
Detailed Segmentation:
- Global Biodefense Market, By Product:
- Anthrax
- Small Pox
- Botulism
- Radiation
- Others
- Global Biodefense Market, By End User:
- Hospitals
- Ambulatory Care Centers
- Research Organizations
- Military
- Others
- Global Biodefense Market, By Region:
- North America
- By Product:
- Anthrax
- Small Pox
- Botulism
- Radiation
- Others
- By End User:
- Hospitals
- Ambulatory Care Centers
- Military
- Others
- By Country:
- U.S.
- Canada
- Latin America
- By Product:
- Anthrax
- Small Pox
- Botulism
- Radiation
- Others
- By End User:
- Hospitals
- Ambulatory Care Centers
- Military
- Others
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Product:
- Anthrax
- Small Pox
- Botulism
- Radiation
- Others
- By End User:
- Hospitals
- Ambulatory Care Centers
- Military
- Others
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia Pacific
- By Product:
- Anthrax
- Small Pox
- Botulism
- Radiation
- Others
- By End User:
- Hospitals
- Ambulatory Care Centers
- Military
- Others
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Product:
- Anthrax
- Small Pox
- Botulism
- Radiation
- Others
- By End User:
- Hospitals
- Ambulatory Care Centers
- Military
- Others
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Product:
- Anthrax
- Small Pox
- Botulism
- Radiation
- Others
- By End User:
- Hospitals
- Ambulatory Care Centers
- Military
- Others
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Emergent Biosolutions Inc.*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- SIGA Technologies Inc.
- Bavarian Nordic A/S
- Elusys Therapeutics Inc.
- Ichor Medical Systems Inc.
- Amgen Inc.
- Cleveland BioLabs Inc.
- Dynavax Technologies Corporation
- Alnylam Pharmaceuticals Inc.
- XOMA Corporation.
“*” marked represents similar segmentation in other categories in the respective section.